Every Form 4 that Celularity Inc (CELUW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CELUW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELUW filings page.
The Philip & Daniele Barach Family Trust, a 10% owner of Celularity Inc., reported changes in its derivative positions. The trust’s option to purchase up to $2,000,000 in convertible notes, which were convertible into 1,807,229 shares of Class A common stock, expired pursuant to its terms on June 19, 2026 without any consideration paid. A related option to obtain up to 839,160 warrants also expired on that date. The filing also lists continuing holdings of warrants and convertible notes that are convertible into 3,707,457 and 1,807,229 shares of Class A common stock, respectively.
Celularity Inc ten percent owner reports expiration of financing options held through a family trust. The Philip & Daniele Barach Family Trust previously held options to purchase up to $2,000,000 in aggregate principal amount of convertible notes and to obtain up to 839,160 related warrants for Celularity Class A common stock.
These options expired according to their terms on June 19, 2026, and the expiration occurred with no consideration paid. The trust is or was the direct owner of all securities reported, while Philip Alan Barach is a trustee with independent voting and disposition power and may be deemed an indirect beneficial owner, subject to his pecuniary interest.
Celularity Inc’s major shareholder, Daniele Wolf Barach, reported changes in derivative positions held through the Philip & Daniele Barach Family Trust. Options to purchase up to $2,000,000 of convertible notes, and related rights to obtain 839,160 warrants, expired on June 19, 2026 with no consideration paid.
The trust continues to hold indirect derivative interests in warrants for 3,707,457 shares of Class A common stock at $2.00 per share, expiring on December 19, 2030, and convertible notes convertible into 1,807,229 shares at $1.66 per share, expiring on December 31, 2026. The reporting person may be deemed an indirect beneficial owner but disclaims beneficial ownership beyond any pecuniary interest.
Celularity Inc. executive Stephen Brigido reported the vesting and conversion of 821 restricted stock units into Class A Common Stock on April 13, 2026. These RSUs were part of a 3,281-unit grant made on April 13, 2022, of which 25% vested on this date.
To cover taxes on the vesting, 268 shares of Class A Common Stock were withheld at a price of $1.28 per share, leaving a net increase of 553 shares from this event. Following these transactions, Brigido directly holds 9,474 shares of Celularity Class A Common Stock.
Celularity Inc Senior Executive Vice President John R. Haines reported the vesting and conversion of 1,641 restricted stock units (RSUs) into 1,641 shares of Class A common stock. The RSUs are part of a 6,562-unit grant made on April 13, 2022, of which 25% vested on April 13, 2026.
To cover tax obligations on this RSU vesting, 583 shares of Class A common stock were withheld at a price of $1.28 per share. After these compensation-related transactions, Haines directly owns 30,179 shares of Celularity Class A common stock. Each RSU is the economic equivalent of one share of Class A common stock.
Celularity Inc Chief Executive Officer Robert J. Hariri reported routine equity compensation activity involving restricted stock units (RSUs). On April 13, 2026, 3,281 RSUs granted on April 13, 2022 vested and converted into 3,281 shares of Class A Common Stock, representing 25% of a 13,123-RSU award.
To cover tax obligations on this vesting, 1,182 shares of Class A Common Stock were withheld at $1.28 per share, a non–open-market disposition. Following these transactions, Hariri directly holds 2,853,553 shares of Celularity Class A Common Stock.